MD+DI Online is part of the Informa Markets Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

HomeBusinessDiving into Medtech's M&A in 2021

Let’s Talk Medtech

Diving into Medtech's M&A in 2021

Glenn Hunzinger, US Pharma & Life Science Leader for PricewaterhouseCoopers discusses the Pharmaceutical and life sciences deals insights: 2021 midyear outlook report. Hunzinger also talks about some trends in medtech M&A and the rise of the Special Purpose Acquisition Corporation mergers. Plus, MD+DI’s Omar Ford gives insight on Illumina’s controversial acquisition of Grail.

Omar Ford | Aug 26, 2021

onephoto-stock.adobe.com

This episode of Let’s Talk Medtech is a double-header. We speak with Glenn Hunzinger, US Pharma & Life Science Leader for PricewaterhouseCoopers about the state of medtech M&A and take a dive into the Pharmaceutical and life sciences deals insights: 2021 midyear outlook report.

Then, Omar Ford, MD+DI’s Managing Editor, delves into the controversial Illumina/Grail merger.

TAGS: Let's Talk Medtech

Hide comments

Load More

Comments

Plain text